Get started
Author

Julian J.K. Lohmeyer

Observed names: J Lohmeyer, Julian J. K. Lohmeyer, Julian Lohmeyer, Lohmeyer, J., Lohmeyer, Julian, Lohmeyer, Julian Johannes Karl
Observed institutions: Goethe University Frankfurt, Universitätsklinikum Würzburg, University Hospital Frankfurt, Stanford Medicine, Stanford Cancer Institute, Stanford University
ORCID: 0000-0001-8077-1910
Observed ORCID: 0000-0001-8077-1910
OpenAlex ID: A5062950885
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
2016 · Constanze Schneider, Thomas Oellerich, et al. · Nature Medicine · 186
PDF
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory
2021 · Ole A. W. Haabeth, Julian J. K. Lohmeyer, et al. · ACS Central Science · 74
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2022 · Tanaya Shree, Vishnu Shankar, et al. · Blood Cancer Discovery · 48
Intratumoral immunotherapy relies on B and T cell collaboration
2022 · Idit Sagiv-Barfi, Debra K. Czerwinski, et al. · Science Immunology · 46
Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner
2018 · J Lohmeyer, T Nerreter, et al. · Clinical & Experimental Immunology · 31
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis
2025 · Julian Ronnacker, Philippe J. Muller, et al. · Leukemia · 15
PDF
miRNA-26b Downregulation in Peripheral Blood Mononuclear Cells of Patients with Hepatitis C Associated Lymphomas is Restored by Successful Interferon-Free Antiviral Therapy
2018 · Jan Peveling-Oberhag, Katrin Bankov, et al. · Antiviral Therapy · 6
Correction: Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
2017 · Constanze Schneider, Thomas Oellerich, et al. · Nature Medicine · 5
PDF
Data from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
Supplementary Figure from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
PDF
Supplementary Figure from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
Supplementary Data from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
Supplementary Figure from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
Supplementary Figure from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
Supplementary Figure from CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
2023 · Tanaya Shree, Vishnu Shankar, et al.
PDF
Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia
2017 · Schneider, C., Oellerich, T., et al. · MPG.PuRe (Max Planck Society)
Behandlung von Hepatitis C-assoziierten Non-Hodgkin-Lymphomen mittels interferonfreier antiviraler Therapie – eine Fallserie
2016 · J Peveling-Oberhag, K Bankov, et al. · Zeitschrift für Gastroenterologie
Works count: 19
Citation count: 411
H-index: 6
I10-index: 6
Year
Topic
Type